Safety of two dosing frequencies of subcutaneous interferon β-1a in patients at high risk of conversion to multiple sclerosis: results of the phase III, randomized, double-blind, placebo-controlled REFLEX trial: P918


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles